Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORION-2 PREVENT: inclisiran for prevention of major cardiovascular events in patients with established cardiovascular disease
CTR20213277Phase 3Active
- Sponsor
- Novartis
- Start
- Mar 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of inclisiran in cardiac morbidity, myocardial infarction (MI), stroke, arteriosclerosis obliterans, sponsored by Novartis. Started Mar 2022; status: active.
02
Drugs
inclisiran
03
Conditions
cardiac morbiditymyocardial infarction (MI)strokearteriosclerosis obliterans
Beyond the preview
Go deeper on CTR20213277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213277.